The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Jakinibs are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.
The global Jakinibs market was valued at US$ 14610 million in 2023 and is anticipated to reach US$ 33210 million by 2030, witnessing a CAGR of 12.4% during the forecast period 2024-2030.
The driving factors of the Janus Kinase (JAK) inhibitor market mainly include the following aspects:
Increase in immune system diseases: JAK inhibitors are commonly used to treat immune system-related diseases such as rheumatoid arthritis, Sjogren's syndrome, inflammatory bowel disease, and psoriasis. As the incidence of these diseases continues to increase, the JAK inhibitor market is also expanding.
Research and development of innovative drugs: Pharmaceutical companies continue to invest in the development of new generations of JAK inhibitors to improve treatment efficacy and reduce side effects. The launch of these innovative drugs drives the growth of the market.
Aging Global Population: As the global population ages, the risk of developing immune system-related diseases increases. This will drive demand for drugs such as JAK inhibitors to address health challenges in the elderly population.
This report aims to provide a comprehensive presentation of the global market for Jakinibs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Jakinibs.
Report Scope
The Jakinibs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Jakinibs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Jakinibs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma, Inc.
Eli Lilly and Co.
Incyte Corp.
Novartis AG
Pfizer Inc.
GSK
Bristol Myers Squibb Co.
Baxter International, Inc.
Gilead Sciences, Inc.
AbbVie, Inc.
Takeda
Boehringer Ingelheim Group
Teva Pharmaceutical
Kyowa Hakko Kirin Co. Ltd.
Segment by Type
JAK1 Inhibitors
JAK2 Inhibitors
JAK3 Inhibitors
Segment by Application
Rheumatoid Arthritis
Inflammatory Bowel Disease
Psoriasis
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Jakinibs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Jakinibs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Jakinibs are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.
The global Jakinibs market was valued at US$ 14610 million in 2023 and is anticipated to reach US$ 33210 million by 2030, witnessing a CAGR of 12.4% during the forecast period 2024-2030.
The driving factors of the Janus Kinase (JAK) inhibitor market mainly include the following aspects:
Increase in immune system diseases: JAK inhibitors are commonly used to treat immune system-related diseases such as rheumatoid arthritis, Sjogren's syndrome, inflammatory bowel disease, and psoriasis. As the incidence of these diseases continues to increase, the JAK inhibitor market is also expanding.
Research and development of innovative drugs: Pharmaceutical companies continue to invest in the development of new generations of JAK inhibitors to improve treatment efficacy and reduce side effects. The launch of these innovative drugs drives the growth of the market.
Aging Global Population: As the global population ages, the risk of developing immune system-related diseases increases. This will drive demand for drugs such as JAK inhibitors to address health challenges in the elderly population.
This report aims to provide a comprehensive presentation of the global market for Jakinibs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Jakinibs.
Report Scope
The Jakinibs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Jakinibs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Jakinibs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma, Inc.
Eli Lilly and Co.
Incyte Corp.
Novartis AG
Pfizer Inc.
GSK
Bristol Myers Squibb Co.
Baxter International, Inc.
Gilead Sciences, Inc.
AbbVie, Inc.
Takeda
Boehringer Ingelheim Group
Teva Pharmaceutical
Kyowa Hakko Kirin Co. Ltd.
Segment by Type
JAK1 Inhibitors
JAK2 Inhibitors
JAK3 Inhibitors
Segment by Application
Rheumatoid Arthritis
Inflammatory Bowel Disease
Psoriasis
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Jakinibs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Jakinibs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Jakinibs Market Overview
1.1 Product Overview and Scope of Jakinibs
1.2 Jakinibs Segment by Type
1.2.1 Global Jakinibs Market Value Comparison by Type (2024-2030)
1.2.2 JAK1 Inhibitors
1.2.3 JAK2 Inhibitors
1.2.4 JAK3 Inhibitors
1.3 Jakinibs Segment by Application
1.3.1 Global Jakinibs Market Value by Application: (2024-2030)
1.3.2 Rheumatoid Arthritis
1.3.3 Inflammatory Bowel Disease
1.3.4 Psoriasis
1.3.5 Others
1.4 Global Jakinibs Market Size Estimates and Forecasts
1.4.1 Global Jakinibs Revenue 2019-2030
1.4.2 Global Jakinibs Sales 2019-2030
1.4.3 Global Jakinibs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Jakinibs Market Competition by Manufacturers
2.1 Global Jakinibs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Jakinibs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Jakinibs Average Price by Manufacturers (2019-2024)
2.4 Global Jakinibs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Jakinibs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Jakinibs, Product Type & Application
2.7 Jakinibs Market Competitive Situation and Trends
2.7.1 Jakinibs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Jakinibs Players Market Share by Revenue
2.7.3 Global Jakinibs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Jakinibs Retrospective Market Scenario by Region
3.1 Global Jakinibs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Jakinibs Global Jakinibs Sales by Region: 2019-2030
3.2.1 Global Jakinibs Sales by Region: 2019-2024
3.2.2 Global Jakinibs Sales by Region: 2025-2030
3.3 Global Jakinibs Global Jakinibs Revenue by Region: 2019-2030
3.3.1 Global Jakinibs Revenue by Region: 2019-2024
3.3.2 Global Jakinibs Revenue by Region: 2025-2030
3.4 North America Jakinibs Market Facts & Figures by Country
3.4.1 North America Jakinibs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Jakinibs Sales by Country (2019-2030)
3.4.3 North America Jakinibs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Jakinibs Market Facts & Figures by Country
3.5.1 Europe Jakinibs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Jakinibs Sales by Country (2019-2030)
3.5.3 Europe Jakinibs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Jakinibs Market Facts & Figures by Country
3.6.1 Asia Pacific Jakinibs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Jakinibs Sales by Country (2019-2030)
3.6.3 Asia Pacific Jakinibs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Jakinibs Market Facts & Figures by Country
3.7.1 Latin America Jakinibs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Jakinibs Sales by Country (2019-2030)
3.7.3 Latin America Jakinibs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Jakinibs Market Facts & Figures by Country
3.8.1 Middle East and Africa Jakinibs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Jakinibs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Jakinibs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Jakinibs Sales by Type (2019-2030)
4.1.1 Global Jakinibs Sales by Type (2019-2024)
4.1.2 Global Jakinibs Sales by Type (2025-2030)
4.1.3 Global Jakinibs Sales Market Share by Type (2019-2030)
4.2 Global Jakinibs Revenue by Type (2019-2030)
4.2.1 Global Jakinibs Revenue by Type (2019-2024)
4.2.2 Global Jakinibs Revenue by Type (2025-2030)
4.2.3 Global Jakinibs Revenue Market Share by Type (2019-2030)
4.3 Global Jakinibs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Jakinibs Sales by Application (2019-2030)
5.1.1 Global Jakinibs Sales by Application (2019-2024)
5.1.2 Global Jakinibs Sales by Application (2025-2030)
5.1.3 Global Jakinibs Sales Market Share by Application (2019-2030)
5.2 Global Jakinibs Revenue by Application (2019-2030)
5.2.1 Global Jakinibs Revenue by Application (2019-2024)
5.2.2 Global Jakinibs Revenue by Application (2025-2030)
5.2.3 Global Jakinibs Revenue Market Share by Application (2019-2030)
5.3 Global Jakinibs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Astellas Pharma, Inc.
6.1.1 Astellas Pharma, Inc. Corporation Information
6.1.2 Astellas Pharma, Inc. Description and Business Overview
6.1.3 Astellas Pharma, Inc. Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Astellas Pharma, Inc. Jakinibs Product Portfolio
6.1.5 Astellas Pharma, Inc. Recent Developments/Updates
6.2 Eli Lilly and Co.
6.2.1 Eli Lilly and Co. Corporation Information
6.2.2 Eli Lilly and Co. Description and Business Overview
6.2.3 Eli Lilly and Co. Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eli Lilly and Co. Jakinibs Product Portfolio
6.2.5 Eli Lilly and Co. Recent Developments/Updates
6.3 Incyte Corp.
6.3.1 Incyte Corp. Corporation Information
6.3.2 Incyte Corp. Description and Business Overview
6.3.3 Incyte Corp. Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Incyte Corp. Jakinibs Product Portfolio
6.3.5 Incyte Corp. Recent Developments/Updates
6.4 Novartis AG
6.4.1 Novartis AG Corporation Information
6.4.2 Novartis AG Description and Business Overview
6.4.3 Novartis AG Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis AG Jakinibs Product Portfolio
6.4.5 Novartis AG Recent Developments/Updates
6.5 Pfizer Inc.
6.5.1 Pfizer Inc. Corporation Information
6.5.2 Pfizer Inc. Description and Business Overview
6.5.3 Pfizer Inc. Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Inc. Jakinibs Product Portfolio
6.5.5 Pfizer Inc. Recent Developments/Updates
6.6 GSK
6.6.1 GSK Corporation Information
6.6.2 GSK Description and Business Overview
6.6.3 GSK Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 GSK Jakinibs Product Portfolio
6.6.5 GSK Recent Developments/Updates
6.7 Bristol Myers Squibb Co.
6.6.1 Bristol Myers Squibb Co. Corporation Information
6.6.2 Bristol Myers Squibb Co. Description and Business Overview
6.6.3 Bristol Myers Squibb Co. Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Bristol Myers Squibb Co. Jakinibs Product Portfolio
6.7.5 Bristol Myers Squibb Co. Recent Developments/Updates
6.8 Baxter International, Inc.
6.8.1 Baxter International, Inc. Corporation Information
6.8.2 Baxter International, Inc. Description and Business Overview
6.8.3 Baxter International, Inc. Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Baxter International, Inc. Jakinibs Product Portfolio
6.8.5 Baxter International, Inc. Recent Developments/Updates
6.9 Gilead Sciences, Inc.
6.9.1 Gilead Sciences, Inc. Corporation Information
6.9.2 Gilead Sciences, Inc. Description and Business Overview
6.9.3 Gilead Sciences, Inc. Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Gilead Sciences, Inc. Jakinibs Product Portfolio
6.9.5 Gilead Sciences, Inc. Recent Developments/Updates
6.10 AbbVie, Inc.
6.10.1 AbbVie, Inc. Corporation Information
6.10.2 AbbVie, Inc. Description and Business Overview
6.10.3 AbbVie, Inc. Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 AbbVie, Inc. Jakinibs Product Portfolio
6.10.5 AbbVie, Inc. Recent Developments/Updates
6.11 Takeda
6.11.1 Takeda Corporation Information
6.11.2 Takeda Jakinibs Description and Business Overview
6.11.3 Takeda Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Takeda Jakinibs Product Portfolio
6.11.5 Takeda Recent Developments/Updates
6.12 Boehringer Ingelheim Group
6.12.1 Boehringer Ingelheim Group Corporation Information
6.12.2 Boehringer Ingelheim Group Jakinibs Description and Business Overview
6.12.3 Boehringer Ingelheim Group Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Boehringer Ingelheim Group Jakinibs Product Portfolio
6.12.5 Boehringer Ingelheim Group Recent Developments/Updates
6.13 Teva Pharmaceutical
6.13.1 Teva Pharmaceutical Corporation Information
6.13.2 Teva Pharmaceutical Jakinibs Description and Business Overview
6.13.3 Teva Pharmaceutical Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Teva Pharmaceutical Jakinibs Product Portfolio
6.13.5 Teva Pharmaceutical Recent Developments/Updates
6.14 Kyowa Hakko Kirin Co. Ltd.
6.14.1 Kyowa Hakko Kirin Co. Ltd. Corporation Information
6.14.2 Kyowa Hakko Kirin Co. Ltd. Jakinibs Description and Business Overview
6.14.3 Kyowa Hakko Kirin Co. Ltd. Jakinibs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Kyowa Hakko Kirin Co. Ltd. Jakinibs Product Portfolio
6.14.5 Kyowa Hakko Kirin Co. Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Jakinibs Industry Chain Analysis
7.2 Jakinibs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Jakinibs Production Mode & Process
7.4 Jakinibs Sales and Marketing
7.4.1 Jakinibs Sales Channels
7.4.2 Jakinibs Distributors
7.5 Jakinibs Customers
8 Jakinibs Market Dynamics
8.1 Jakinibs Industry Trends
8.2 Jakinibs Market Drivers
8.3 Jakinibs Market Challenges
8.4 Jakinibs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
